References
Chobanian A, Bakris G, Black H, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003, 42:1206–1252.
Staples A, Wong C: Risk factors for progression of chronic kidney disease. Curr Opin Pediatr 2010, 22:161–169.
Bakris GL: Slowing nephropathy progression: focus on proteinuria reduction. Clin J Am Soc Nephrol 2008, 3(Suppl 1):S3–S10.
Parving HH, Lehnert H, Bröchner-Mortensen J, et al.; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001, 345:870–878.
Jafer TH, Schmid CH, Landa M, et al.; for the ACE Inhibition in Progressive Renal Disease Study Group: Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001, 135:73–87
Flynn JT, Mitsnefes M, Pierce C, et al.: Blood pressure in children with chronic kidney disease: a report from the Chronic Kidney Disease in Children study. Hypertension 2008, 52:631–637.
Disclosure
No potential conflict of interest relevant to this article was reported.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Siragy, H.M. ESCAPE: From Hypertension to Renal Failure. Curr Hypertens Rep 12, 207–209 (2010). https://doi.org/10.1007/s11906-010-0124-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11906-010-0124-4